Scientific Advances and New Frontiers in Mesothelioma Therapeutics

Luciano Mutti; Tobias Peikert; Bruce W.S. Robinson; Arnaud Scherpereel; Anne S. Tsao; Marc de Perrot; Gavitt A. Woodard; David M. Jablons; Jacinta Wiens; Fred R. Hirsch; Haining Yang; Michele Carbone; Anish Thomas; Raffit Hassan

doi:10.1016/j.jtho.2018.06.011

Scientific Advances and New Frontiers in Mesothelioma Therapeutics

Luciano Mutti, Tobias Peikert, Bruce W.S. Robinson, Arnaud Scherpereel, Anne S. Tsao, Marc de Perrot, Gavitt A. Woodard, David M. Jablons, Jacinta Wiens, Fred R. Hirsch, Haining Yang, Michele Carbone, Anish Thomas, Raffit Hassan

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Review article › peer-review

81 Scopus citations

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.

Original language	English (US)
Pages (from-to)	1269-1283
Number of pages	15
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	9
DOIs	https://doi.org/10.1016/j.jtho.2018.06.011
State	Published - Sep 2018

Keywords

Biomarkers
Chemotherapy
Immunotherapy
Malignant pleural mesothelioma
Oncology therapeutics

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jtho.2018.06.011

Cite this

@article{82d8d8fc82304ba0ab03892eac51034f,

title = "Scientific Advances and New Frontiers in Mesothelioma Therapeutics",

abstract = "Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.",

keywords = "Biomarkers, Chemotherapy, Immunotherapy, Malignant pleural mesothelioma, Oncology therapeutics",

author = "Luciano Mutti and Tobias Peikert and Robinson, {Bruce W.S.} and Arnaud Scherpereel and Tsao, {Anne S.} and {de Perrot}, Marc and Woodard, {Gavitt A.} and Jablons, {David M.} and Jacinta Wiens and Hirsch, {Fred R.} and Haining Yang and Michele Carbone and Anish Thomas and Raffit Hassan",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = sep,

doi = "10.1016/j.jtho.2018.06.011",

language = "English (US)",

volume = "13",

pages = "1269--1283",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "9",

}

TY - JOUR

T1 - Scientific Advances and New Frontiers in Mesothelioma Therapeutics

AU - Mutti, Luciano

AU - Peikert, Tobias

AU - Robinson, Bruce W.S.

AU - Scherpereel, Arnaud

AU - Tsao, Anne S.

AU - de Perrot, Marc

AU - Woodard, Gavitt A.

AU - Jablons, David M.

AU - Wiens, Jacinta

AU - Hirsch, Fred R.

AU - Yang, Haining

AU - Carbone, Michele

AU - Thomas, Anish

AU - Hassan, Raffit

PY - 2018/9

Y1 - 2018/9

N2 - Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.

AB - Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.

KW - Biomarkers

KW - Chemotherapy

KW - Immunotherapy

KW - Malignant pleural mesothelioma

KW - Oncology therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85052299232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052299232&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.06.011

DO - 10.1016/j.jtho.2018.06.011

M3 - Review article

C2 - 29966799

AN - SCOPUS:85052299232

SN - 1556-0864

VL - 13

SP - 1269

EP - 1283

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 9

ER -

Scientific Advances and New Frontiers in Mesothelioma Therapeutics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this